Genexis Biotech raises Rs 4 Cr in seed round led by GVFL

Vadodara-based bio-manufacturing startup Genexis Biotech has raised Rs 4 crore in a seed funding round led by GVFL, with participation from Benzai10. 

The proceeds will be used to scale bioreactor capacity, build downstream processing infrastructure, launch new recombinant proteins and enzymes, and strengthen compliance, sales, and distribution functions.

Genexis Biotech develops animal-origin-free recombinant proteins using precision fermentation, catering to sectors like biopharma, food-tech, and cell culture. The startup operates a certified Class 10,000 facility and is setting up a GMP-compliant unit.

It has introduced recombinant peptidases such as amino peptidase and enterokinase, and plans to launch recombinant transferrin and albumin.

In the past year, Genexis established partnerships with pharmaceutical companies and biotech firms, signed an MoU with the Gujarat government, and received client orders for alternative protein formulations. It showcased its portfolio at Global Bio-India 2024 and aims to enter the regulated biotech export market, develop encapsulated formulations for the cosmetics industry, and collaborate with CDMOs, academic labs, and biopharma firms.

Genexis Biotech focuses on scalable, ethical biomolecule production. GVFL has backed the company as part of its investment thesis across deeptech and biotech innovation.